ReviewBlood research2026
FLT3-mutated AML: standards of care and ongoing investigation.
Review in Blood research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute myeloid leukemia (AML) is characterized by the rapid, unchecked clonal proliferation of myeloid precursor cells. It is the most common type of acute leukemia in adults and exhibits significant molecular heterogeneity. FLT3 mutations are among the most common and well-described genetic mutations in AML; they worsen overall survival and increase the relapse rate. Treatment options for FLT3-mutated AML are rapidly expanding, with an increasing number of FLT3 inhibitors being incorporated into treatment regimens. This review provides an overview of the role of FLT3 inhibitors in the current standard of care therapy in both the newly diagnosed and relapsed/refractory settings. Additionally, it highlights the areas of key ongoing investigations in the treatment of FLT3-mutated AML.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.